CARMAT Company

CARMAT is a medtech company, offering biocompatible, auto-regulated total artificial hearts, including right and left ventricles designed to be as close as possible to the human heart. It is designed for patients suffering from chronic terminal heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction. CARMAT’s aim is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients, who are not eligible for a transplant and who have exhausted every drug-related possibility. It was launched in 2008 by [Philippe Pouletty]( and is based in Vélizy-villacoublay.

Headquarters: France
Industry: Healthcare
Funding Status: IPO
Technology: Artificial Intelligence, Health Care, Information Technology
Founded Date: 2008